| BIAsp 30 (biphasic insulin aspart 30/70 biosimilar) / Novo Nordisk |
ChiCTR-IPR-15006834: The efficacy and safety for T2DM patients with OAD losing efficacy receiving insulin aspart 30 plus metformin compared with insulin aspart 30 monotherapy |
|
|
| Recruiting | 4 | 256 | | insulin aspart 30 (NovoMix30) and metformin (Glucophage) combination group ;insulin aspart 30 (NovoMix30) monotherapy group | Beijing Hospital; Beijing Hospital, Merck Serono | T2DM | | | | |
ChiCTR1900021970: Efficacy and safety of beinaglutide (formerly known as benaglutide) versus insulin aspart 30 as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin alone: a prospective, multi-centric, randomized, open-labeled, parallel-group study. |
|
|
| Recruiting | 4 | 420 | | benaglutide plus metformin ;biphasic insulin aspart 30 plus metformin | Peking University People's Hospital; Shanghai Benemae Pharmaceutical Corporation, Shanghai Benemae Pharmaceutical Corporation | Type 2 Diabetes | | | | |
ChiCTR2200062688: A randomized, double-blinded, parallel-controlled clinical study to investigate the blood glucose fluctuation of mulberry twig (Ramulus Mori, Sangzhi) alkaloid tablet in patients with Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | 4 | 150 | | investigational product+NovoMix30 ;placebo+NovoMix30 | Tianjin Medical University Chu Hsien-I Memorial Hospital; Tianjin Medical University Chu Hsien-I Memorial Hospital, Beijing Wuhe Bo'ao Pharmaceutical Co., Ltd | Type 2 Diabetes Mellitus | | | | |
2005-004775-38: A comparison of pharmacodynamics and pharmacokinetics of Insulin Aspart and Biphasic Insulin Aspart 30, 50 og 70. A quadruple cross-over trial. |
|
|
| Ongoing | 3/4 | 24 | Europe | Bifasisk insulin aspart 30 (BIAsp 30), Insulin Aspart, Bifasisk Insulin Aspart 50, Bifasisk insulin Aspart 70, BIAsp 50, BIAsp 70, | Medicinsk Afd. M, Århus Sygehus, Nørrebrogade | Patients with type 1 diabetes | | | | |
